Omni Bio Pharmaceutical Inc

Omni Bio Pharmaceutical — Investor Presentation (June 2014)

26 slides from Omni Bio Pharmaceutical's investor presentation, Jun 3, 2014

  1. Slide 1: Omni Bio Pharmaceutical, Inc. Company Overview

    Slide 1: Omni Bio Pharmaceutical, Inc. Company Overview

    Omni Bio Pharmaceutical, Inc. Creating Breakthrough Therapies Company Overview Bruce Schneider, CEO June, 2014 %

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward-looking statements. The forward-looking statements in this presentation are based on information available to us as of the date any such statements are made and w

  3. Slide 3: Omni Facts

    Slide 3: Omni Facts

    ~Omni Facts e Public company since 2009 (symbol OMBP.OB) e Initially formed to license & promote patents for new uses of plasma-derived alpha-1 antitrypsin (p-AAT) e Now developing “Enbrel-like” recombinant Fc fusion proteins (Fc-AATs) e Multiple high value, medically important disease targets e US

  4. Slide 4: Management team: CEO, CSO, CDO

    Slide 4: Management team: CEO, CSO, CDO

    4 4% CEO cso cDO Bruce Schneider, PhD Charles Dinarello, MD Bruce Forrest, MD * Over 35 years drug + World recognized * Over 25 years development “father” of cytokine experience in experience biology immunology & drug * Most recently EVP & * Current affiliations with development Chief of Research U.

  5. Slide 5: Plasma-derived AAT (p-AAT)

    Slide 5: Plasma-derived AAT (p-AAT)

    ~ SS Plasma-derived AAT (p-AAT) e Protease inhibitor with profound anti- inflammat and tissue protective effects e Extracted & purified from whole human blood e Currently approved to treat AAT-deficient patients » Emphysema, COPD * Once weekly IV infusions * 25-year safety record « High cost (~$100K

  6. Slide 6: Recombinant Fc-AAT

    Slide 6: Recombinant Fc-AAT

    ~ Recombinant Fc-AAT e Exciting New Opportunity Recombinant AAT “uN 40-50x more potent than p-AAT in various animal models Improved stability and longer duration of effect Simpler and lower cost manufacturing with no risk of viral contamination Human IgG1-Fe Typical safety and efficacy risk mitigate

  7. Slide 7: Value Creation Opportunities

    Slide 7: Value Creation Opportunities

    Value Creation Opportunities Clinical Proof of Principle Options for Fc-AAT Monetization of p-AAT Method of Use Patents + Guided by emerging p-AAT data in disease areas with: - High unmet need (e.g., GvHD, diabetes, chronic gout) - Easy to measure clinical endpoints - Drug effects able to be seen qu

  8. Slide 8: Fc-AAT Market Potential

    Slide 8: Fc-AAT Market Potential

    -Fc-AAT Market Rotantial Potential First New Indications Market Size (US/EU) Graft vs Host Disease ~$500M Type 1 Diabetes (Early Onset) >$1B Gout (Treatment Refractory) >$1B Life Cycle Management Options Market Size (US/EU) Replacement Therapy >$500M Rheumatoid Arthritis >$1B Inflammatory Bowel Dise

  9. Slide 9: Fc-AAT Development Plan

    Slide 9: Fc-AAT Development Plan

    Fc-AAT Development Plan* wir EE Bae aT EI eTevTavlavlTevlTatTafvay ee Taya TS Te TavTeleToafalTewla Ta fale FeAAT Early Devdlopment Plan (Overview) — Pre-Ciinioal Animal Phi Coll Line Opt Eatly Analytical Assay: *Specifictiming subjectto funding availability OF niBio 9

  10. Slide 10: Investment Required to Achieve Critical Fc-AAT Milestones

    Slide 10: Investment Required to Achieve Critical Fc-AAT Milestones

    _— SS Investment Required to Achieve Critical Fc-AAT Milestones* $7-8M $2-3 M Now 2H’2015 Complete Conduct Preclinical 1st Human Development Trials + Process/formulation! + Phase 1 clinical trials analytical development + Initial safety, pkipd & + Ancillary pharmacology biomarker data & pilot toxico

  11. Slide 11: Strategic Options for Fc-AAT

    Slide 11: Strategic Options for Fc-AAT

    Development trategic Options for Fo-AAT Develop Alone Through Phase 2a Co-Develop with Partner Out-License To Pharma Co. + 3-4 year outlook + Potential 5-10x value play * Funding of ~$15M required 1-3 year outlook Realizable following successful milestones from cell line optimization onward Lowers s

  12. Slide 12: p-AAT Licensing Supported by Emerging Clinical Data

    Slide 12: p-AAT Licensing Supported by Emerging Clinical Data

    -p-AAT Licensing Supported by Emerging Clinical Data Type 1 Diabetes Graft vs Host Disease (GvHD)/ Acute Myocardial Infarction e Three pilot studies completed e Immune Tolerance Network ° Kamada © Omni Bio Loss of pancreatic beta cell function slowed or halted in certain patients Pivotal trials with

  13. Slide 13: Sub-licensable Method of Use Patent Areas

    Slide 13: Sub-licensable Method of Use Patent Areas

    Sub-licensable Method of Use Patent Areas* e Diabetes (Type 1 and Type 2) e Graft vs. host disease (GVHD) e Non-organ transplantation rejection e Post myocardial infarction remodeling e Certain bacterial and viral infections e Radioprotection * Licensed method-of-use patents issued or pending in the

  14. Slide 14: Ongoing Value Drivers

    Slide 14: Ongoing Value Drivers

    ‘Ongoing Value Drivers Next 12 Months Following 12-18 Months e Ex-US Fe-AAT patent issuances e Additional p-AAT use patent issuances e Patient advocacy group alliances e Publication of Omni p-AAT Type 1 diabetes trial (early release available) e Ongoing clinical trial updates on use of p-AAT in diab

  15. Slide 15: Corporate Information

    Slide 15: Corporate Information

    e Stock symbol e Closing stock price (6/1/14) e 52-week range e Shares outstanding e Fully diluted shares e Market capitalization (6/1/14) e Cash on hand (4/30/14)* ‘inclusive of $2 million credit line from lead investor. OP riBio 15 Corporate Information OMBP.OB $0.26 $0.12-0.50 38.4 million 71.6 m

  16. Slide 16: Summary

    Slide 16: Summary

    - Summary e Centerpiece recombinant Fc-AAT program has very broad, high value potential e Several medically important targets identified e Development plan expected to have lower than average risk e Experienced management/scientific team in place e Emerging clinical data expected to support p-AAT pa

  17. Slide 17: Appendix

    Slide 17: Appendix

    Appendix Representative Data Slides OF riBio 17

  18. Slide 18: Fc-AAT Prolongs Mouse AAT Concentrations Compared to p-AAT

    Slide 18: Fc-AAT Prolongs Mouse AAT Concentrations Compared to p-AAT

    c-AAT Prolongs Mouse AAT Concentrations Compared to p-AAT 4.0 ae N=6 =e 38 N=5 =m rAAT-Fe2 (10mg/kg) = 60 > 3.0 —® pAAT (10ma/kg) = 5.0 —™ pAAT (60mg/kg) 28 Ban —* AAT-Fe (2mg/kg) S 20 a 3.0 gts 20 B10 1.0 a 0.5 0.0 ef 051 2 3 4 5 6 7 8 9 day a2 4 T ala 10 12 14day Bs is 2 2s s Zoos 35 bi a 3 &= & 6

  19. Slide 19: Fc-AAT Highlights — Inflammation (1)

    Slide 19: Fc-AAT Highlights — Inflammation (1)

    Fc-AAT Highlights — Inflammation (1) Fc-AAT produces dose-dependent reductions in joint inflammation in gout arthritis model Joint swelling (0-3) 2.07 — p<0.001 120: p<0.001 100 154 => 7 k 80 1.04 £ 60 40 0.54 = 20° 0.0- T T T o 2 2 eo eo - * - es er PS e “ € RN © “ “ NK S KS S Zea = s KS Rs v 3 a r

  20. Slide 20: Fc-AAT Highlights — Inflammation (2)

    Slide 20: Fc-AAT Highlights — Inflammation (2)

    Fc-AAT Highlights — Inflammation (2) Fe-AAT highly effective in clearing granular infiltrates that cause inflammation in gout model Ivig 50ug 4 hours after chemical-induced inflammation 20 OP niBio

  21. Slide 21: Fc-AAT Highlights — Inflammation (3)

    Slide 21: Fc-AAT Highlights — Inflammation (3)

    Fc-AAT Highlights — Inflammation (3) Joint swelling (0-3) Fc-AAT 50 mcg at least as effective as p-AAT 2 mg and competitive with high-dose IL1-Ra (anakinra) in gout model p<0.001 1 aan Te p<0.001 pd. . rH p<0.001 e —— 1.0: & 15 a = 3 10 é : = os 8 0.0. 7 T T 2 e 2 Pl ~ J & RS & < 4 hours after chemi

  22. Slide 22: Data Highlights — Type 1 Diabetes

    Slide 22: Data Highlights — Type 1 Diabetes

    Data Highlights — Type 1 Diabetes p-AAT treatment preserves islet cell function (essential for insulin production) Insulin Glucagon g° A Bere Es Control ) —LinsulintAAT ee 2 + Insulin Control 8 é Cc ° 6) 00 160 200 260 300 p-AAT Treated i Days after initial therapy i i Islet histology of spontaneous

  23. Slide 23: Type 1 Diabetes - Pilot Study of p-AAT

    Slide 23: Type 1 Diabetes - Pilot Study of p-AAT

    Type 1 Diabetes - Pilot Study of p-AAT 8-week dosing in patients suggests stabilization of C-peptide levels C-peptide Mean 2-hour AUC (pmolimL) 2.0 1.5 1.0 0.5 0.0 woemectooeee- 0 100 200 Study Day = Pediatric == Adult Mean change from baseline: + Adult: +0.013 (p=0.852) + Pediatric: -0.191 (p=0.148

  24. Slide 24: Data Highlights — Graft vs Host Disease

    Slide 24: Data Highlights — Graft vs Host Disease

    Data Highlights — Graft vs Host Disease p-AAT reduces mortality from GvHD in mouse transplant model 100 ad __ 80 = -@® Matched Transplant (n=8) = 60 2 -f& Mis-matched Transplant (n=9) = 40 a -¥ Mis-matched Transplant 20 + p-AAT (n=9) i) 0 10 20 30 40 50 60 70 Days after BMT Tawara| et al. PNAS 2012;

  25. Slide 25: Data Highlights — Cardiac Re-Modeling

    Slide 25: Data Highlights — Cardiac Re-Modeling

    - Data Highlights — Cardiac Re-Modeling p-AAT reduces acute myocardial infarct size in mouse model Albumin Infarct N=6pergroup * P<0.05vssham ** P<0.05 vs Albumin Toldo et al. (2011) J Mol Cell Cardiol §1(2): 244-61 25 OP niBio

  26. Slide 26: Fc-AAT Highlights — Cardiac Re-modeling

    Slide 26: Fc-AAT Highlights — Cardiac Re-modeling

    c-AAT Highlights — Cardiac Re- modeling Fc-AAT reduces infarct size & improves systolic function in mouse model = us 2 YB 100 ws ges * Be + 5” Ss & HE ns 33 ee 28 75 83 Be so S$ Be * ee Vehicle AAT-Fc \gG1 (0.2ml) —(2mg/kg) (2 me/ke) z OP niBio

Source: SEC EDGAR · 8-K filed Jun 3, 2014

More decks from Omni Bio Pharmaceutical Inc